INS and Hypoglycemia: Similarly to inTandem1, there was a significant reduction in HbA1c, weight, fasting glucose and insulin doses, with a 24‐week continuous glucose monitoring (CGM) sub‐study showing increased time in range and decreased postprandial excursions in glucose without an increase in hypoglycaemia.